Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

A sharper focus

The enthusiasm for massive M&A deals is set to redraw industry boundaries

The industry's reawakened enthusiasm for massive M&A deals is set to redraw industry boundaries - particularly if Pfizer is eventually successful with its huge $106bn proposal to acquire AstraZeneca.

There's certainly been no shortage of big deals this month, as the likes of Bristol-Myers Squibb, Lundbeck and Bayer struck out on the acquisition trail.

Perhaps the most intriguing element of this sudden rash of M&A activity was the $16bn Novartis-GlaxoSmithKline 'asset swap', which will see Novartis pick up GSK's oncology portfolio, hand the British company most of its vaccines interests and merge its consumer healthcare business with that of GSK.

The deal will redefine the identity of GSK and Novartis over time and finds further reflection this month in other developments. Merck & Co decided to step away from consumer healthcare, selling its interests in the area - and brands such as Claritin - to Bayer for $14.2bn, and Reckitt Benckiser is considering its pharma future.

Coming after the Abbott/AbbVie and Pfizer/Zoetis splits of the last 18 months, we should expect more of these kinds of deals as companies seek to ruthlessly sharpen their focus.

  • This article was originally published as the editor's comment in PME May 2014


Article by
Dominic Tyer

editorial director of PMGroup

16th May 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics